Research programme: KLH-conjugated vaccines - Stellar Biotechnologies

Drug Profile

Research programme: KLH-conjugated vaccines - Stellar Biotechnologies

Alternative Names: Keyhole limpet haemocyanin conjugated vaccine - Stellar; PSII-KLH conjugate

Latest Information Update: 22 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Guelph
  • Developer Matrivax
  • Class Bacterial polysaccharides; Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Clostridium infections

Most Recent Events

  • 13 Mar 2017 Preclinical development is ongoing for Clostridium-infections in Canada and USA
  • 06 Mar 2017 Matrivax in-licenses PSII technology from Stellar Biotechnologies
  • 06 Mar 2017 Stellar Biotechnologies terminates its license with University of Guelph for PSII technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top